Los Angeles Capital Management LLC Intercept Pharmaceuticals, Inc. Transaction History

Los Angeles Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$14.28 - $19.53 $600,459 - $821,216	-42,049 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$12.99 - $20.47 $28,707 - $45,238	-2,210 Reduced 4.99%	42,049 $624,000
Q2 2021 Aug 05, 2021	BUY	$15.46 - $24.5 $255,182 - $404,397	16,506 Added 59.47%	44,259 $884,000
Q1 2021 May 05, 2021	SELL	$19.33 - $37.75 $237,063 - $462,966	-12,264 Reduced 30.65%	27,753 $640,000
Q4 2020 Feb 04, 2021	BUY	$24.48 - $42.47 $594,545 - $1.03 Million	24,287 Added 154.4%	40,017 $988,000
Q3 2020 Nov 02, 2020	SELL	$39.09 - $53.44 $195,020 - $266,612	-4,989 Reduced 24.08%	15,730 $652,000
Q2 2020 Aug 05, 2020	BUY	$46.7 - $92.04 $268,011 - $528,217	5,739 Added 38.31%	20,719 $992,000
Q4 2019 Feb 07, 2020	BUY	$57.36 - $124.1 $434,788 - $940,678	7,580 Added 102.43%	14,980 $1.86 Million
Q3 2019 Nov 07, 2019	BUY	$58.69 - $80.46 $255,477 - $350,242	4,353 Added 142.86%	7,400 $491,000
Q2 2019 Jul 29, 2019	SELL	$77.77 - $120.68 $1,555 - $2,413	-20 Reduced 0.65%	3,047 $242,000
Q1 2019 Apr 25, 2019	BUY	$91.83 - $120.68 $281,642 - $370,125	3,067 New	3,067 $343,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.